SCHEMBL31748895

SCHEMBL31748895

Cc1ccc(S(=O)(=O)OCCn2cnc3ccccc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.58
HTT P42858 6/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
LMNA P02545 8/20 0.55
ALDH1A1 P00352 3/20 0.55
PKM P14618 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
POLB P06746 1/20 0.53
ALDH3A1 P30838 1/20 0.53
NOD1 Q9Y239 1/20 0.53
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 2/20 0.49
STAT3 P40763 1/20 0.49
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
RAB9A P51151 1/20 0.48
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14281049 0.79 SMN1; SMN2 (0.84) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL9037283 0.77 CYP24A1 (0.53) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL3158247 0.75 ALDH1A1 (0.47) SMN1; SMN2HTTLMNAALDH1A1PKM
SCHEMBL1581431 0.75 PTGS2 (0.62) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL6609665 0.74 HSD11B1 (0.47) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL8211578 0.74 ALDH1A1 (0.44) SMN1; SMN2HTTKMT2AALDH1A1POLB
SCHEMBL1024585 0.73 SMN1; SMN2 (0.73) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL352045 0.73 SMN1; SMN2 (0.96) SMN1; SMN2HTTMEN1KMT2ALMNA
SCHEMBL31662452 0.73 CA12 (0.42) LMNAALDH1A1STAT3GAA
SCHEMBL351186 0.72 SMN1; SMN2 (1.00) SMN1; SMN2HTTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN SHANGHAI INC (CN) 2025-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE ERBB2, MUSK, ERBB3 SMN1; SMN2 607/4885HTT 1802/4885MEN1 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.